Latest On Lexicon Pharmaceuticals, Inc (LXRX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-27 03:40 EST | News | Lexicon's sotagliflozin wins FDA nod for heart failure; up 11% after hours | N/A |  |
| 2023-05-20 02:16 EST | News | Lexicon Pharmaceuticals: May 27 PDUFA Date For Heart Failure Drug Looks Crucial | N/A | |
| 2023-05-03 00:17 EST | News | Lexicon Pharmaceuticals GAAP EPS of -$0.17 beats by $0.01, revenue of $0.02M misses by $0.01M | N/A | |
| 2023-05-03 00:17 EST | News | Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-03-07 21:33 EST | News | Lexicon initiated at buy at Jefferies on uptake of heart failure candidate sotagliflozin | N/A | |
About Lexicon Pharmaceuticals, Inc (LXRX):
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
General
- Name Lexicon Pharmaceuticals, Inc
- Symbol LXRX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 78
- Last Split Factor1:7
- Last Split Date2015-05-21
- Fiscal Year EndDecember
- IPO Date2000-04-07
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.lexpharma.com
Valuation
- Trailing PE 3.74
- Price/Sales (Trailing 12 Mt.) 24.56
- Price/Book (Most Recent Quarter) 11.79
- Enterprise Value Revenue 39.27
- Enterprise Value EBITDA 2.92
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.62
- Next Year EPS Estimate -$0.47
- Next Quarter EPS Estimate -$0.16
- Profit Margin -244%
- Operating Margin -722%
- Return on Assets -35%
- Return on Equity -43%
- Revenue 24 million
- Earnings Per Share $0.37
- Revenue Per Share $0.22
- Gross Profit -129055000
- Quarterly Earnings Growth -97.7%
Highlights
- Market Capitalization 917.37 million
- EBITDA 82.53 million
- PE Ratio -3.09
- PEG Ratio -0.14
- Analyst Target Price $9
- Book Value Per Share $1.11
Share Statistics
- Shares Outstanding 144.35 million
- Shares Float 55.35 million
- % Held by Insiders 90%
- % Held by Institutions 91.96%
- Shares Short 3.59 million
- Shares Short Prior Month 4.49 million
- Short Ratio 1.56
- Short % of Float 6%
- Short % of Shares Outstanding 3%
Technicals
- Beta 1.71
- 52 Week High $9.43
- 52 Week Low $1.03
- 50 Day Moving Average 7.65
- 200 Day Moving Average 3.78
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Lexicon Pharmaceuticals, Inc (LXRX) Dividend Calendar:
Lexicon Pharmaceuticals, Inc (LXRX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Lexicon Pharmaceuticals, Inc (LXRX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Lexicon Pharmaceuticals, Inc (LXRX) Chart:
Lexicon Pharmaceuticals, Inc (LXRX) News:
Below you will find a list of latest news for Lexicon Pharmaceuticals, Inc (LXRX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Lexicon Pharmaceuticals, Inc (LXRX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest LXRX Trades:
Lexicon Pharmaceuticals, Inc (LXRX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-30 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-10-30 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-10-29 | 8-K (Current report) | |
| 2020-10-22 | 8-K (Current report) | |
| 2020-09-29 | 8-K (Current report) | |
| 2020-09-24 | 8-K (Current report) | |
| 2020-09-11 | 8-K (Current report) | |
| 2020-09-08 | 8-K (Current report) | |
| 2020-08-04 | 8-K (Current report) | |
| 2020-07-30 | 8-K (Current report) | |
| 2020-07-30 | 8-K (Current report) | |
| 2020-07-29 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-29 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-07-15 | 8-K (Current report) | |
| 2020-05-29 | 8-K (Current report) | |
| 2020-05-29 | 8-K (Current report) | |
| 2020-04-27 | 8-K (Current report) | |
| 2020-04-27 | 8-K (Current report) | |
| 2020-04-27 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-04-27 | 4 (Statement of changes in beneficial ownership of securities) | |
Lexicon Pharmaceuticals, Inc (LXRX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Lexicon Pharmaceuticals, Inc (LXRX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 90%
Institutional Ownership: 9196%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-04-26 | CHRISTOPHER J SOBECKI | Director | Buy | 3,466.00 | 140,759.00 | | ||
| 2020-04-26 | Frank Palantoni | Director | Buy | 3,466.00 | 16,368.00 | | ||
| 2020-04-26 | Judith L Swain | Director | Buy | 3,466.00 | 16,368.00 | | ||
| 2020-04-26 | Philippe Amouyal | Director | Buy | 3,466.00 | 16,368.00 | | ||
| 2020-04-26 | ROBERT J MD LEFKOWITZ | Director | Buy | 3,466.00 | 16,368.00 | | ||
| 2020-04-26 | ALAN S NIES | Director | Buy | 3,466.00 | 17,082.00 | | ||
| 2020-04-26 | RAYMOND DEBBANE | Director | Buy | 3,466.00 | 316,883.00 | | ||
| 2020-04-26 | SAM L BARKER | Director | Buy | 3,466.00 | 55,653.00 | | ||
| 2020-04-22 | ALAN J MAIN | EVP, Commercial Supply Ops | Buy | 19,893.00 | 111,453.00 | | ||
| 2020-04-22 | JEFFREY L WADE | EVP, Corp Adm Affairs and CFO | Buy | 26,525.00 | 125,146.00 | | ||
| 2020-04-22 | Brian T Crum | VP, General Counsel & Secr. | Buy | 19,893.00 | 56,130.00 | | ||
| 2020-04-22 | Alexander A Santini | EVP and CCO | Buy | 19,893.00 | 62,397.00 | | ||
| 2020-04-22 | James F Tessmer | VP, Finance & Accounting | Buy | 13,262.00 | 69,124.00 | | ||
| 2020-04-22 | PRAVEEN TYLE | EVP, R&D | Buy | 19,893.00 | 74,188.00 | | ||
| 2020-04-22 | Pablo Lapuerta | EVP and CMO | Buy | 19,893.00 | 92,532.00 | | ||
| 2020-02-28 | ALAN J MAIN | EVP, Commercial Supply Ops | Buy | 22,373.00 | 104,319.00 | | ||
| 2020-02-28 | JEFFREY L WADE | EVP, Corp Adm Affairs and CFO | Buy | 25,290.00 | 114,646.00 | | ||
| 2020-02-28 | PRAVEEN TYLE | EVP, R&D | Buy | 2,990.00 | 17,969.00 | | ||
| 2020-02-28 | Alexander A Santini | EVP and CCO | Buy | 2,353.00 | 21,014.00 | | ||
| 2020-02-28 | LONNEL COATS | President and CEO | Buy | 8,390.00 | 235,929.00 | |